Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Commerce Bank

Commerce Bank reduced its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 13,530 shares of the specialty pharmaceutical company’s stock after selling 305 shares during the quarter. Commerce Bank’s holdings in Supernus Pharmaceuticals were worth $422,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Segall Bryant & Hamill LLC purchased a new position in shares of Supernus Pharmaceuticals in the third quarter valued at $791,000. Quest Partners LLC purchased a new position in Supernus Pharmaceuticals during the 3rd quarter valued at about $241,000. Natixis Advisors LLC lifted its holdings in shares of Supernus Pharmaceuticals by 14.9% in the third quarter. Natixis Advisors LLC now owns 39,318 shares of the specialty pharmaceutical company’s stock valued at $1,226,000 after purchasing an additional 5,113 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Supernus Pharmaceuticals by 1.1% in the third quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock valued at $23,163,000 after purchasing an additional 7,833 shares during the last quarter. Finally, GSA Capital Partners LLP increased its stake in shares of Supernus Pharmaceuticals by 218.2% during the 3rd quarter. GSA Capital Partners LLP now owns 62,831 shares of the specialty pharmaceutical company’s stock worth $1,959,000 after purchasing an additional 43,086 shares in the last quarter.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN opened at $36.14 on Wednesday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $39.37. The company has a market capitalization of $2.00 billion, a PE ratio of 33.78 and a beta of 0.86. The stock has a fifty day moving average of $33.81 and a two-hundred day moving average of $31.14.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The firm had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. During the same period in the prior year, the firm posted ($0.29) earnings per share. The business’s quarterly revenue was up 14.2% compared to the same quarter last year. As a group, equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 125,000 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the transaction, the chief executive officer now owns 926,172 shares of the company’s stock, valued at $33,971,988.96. This trade represents a 11.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Georges Gemayel sold 14,213 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total transaction of $520,480.06. Following the completion of the transaction, the director now owns 13,315 shares in the company, valued at approximately $487,595.30. This trade represents a 51.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 154,213 shares of company stock worth $5,660,180 in the last three months. Company insiders own 9.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on SUPN shares. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.